Perioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors
Journal of Surgical Oncology · 2026-11 · 134 (6) · 830-839
DOI: 10.1002/jso.70352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 06.08.2026. Verfasst von Amir Ebadinejad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Pancreatectomy, Hepatectomy, Pancreatic Neoplasms, Neuroendocrine Tumors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives Pancreatic neuroendocrine tumors (pNETs) account for 1%–2% of pancreatic tumors, with an increasing incidence. The safety of concurrent pancreas‐liver resections remains uncertain. This study evaluated the national outcomes of concurrent pancreatectomy and liver‐directed surgery for pNETs.
Methods
ACS‐NSQIP (2019–2023) was queried for adult patients who underwent pancreatectomy for pNETs. Concurrent liver‐directed procedures were identified by CPT code and classified as hepatectomy or ablation alone; patients were grouped as isolated pancreatectomy, concurrent hepatectomy, or concurrent ablation alone. Pre‐, intra‐, and postoperative characteristics were compared using inferential statistics. Multivariable logistic regression identified predictors of 30‐day morbidity, readmission, reoperation, and mortality, with Firth penalized likelihood used for rare outcomes.
Results
Of 4794 patients, 4587 (95.7%) underwent isolated pancreatectomy, 172 (3.6%) underwent concurrent hepatectomy, and 35 (0.7%) underwent concurrent ablation alone. Concurrent hepatectomy was parenchymal‐sparing in 163 of 172 patients (94.8%); only nine patients underwent a major hepatectomy. Overall morbidity was similar across groups (38.8%, 45.9%, and 42.9%; p = 0.154), as was serious morbidity (28.7%, 27.9%, 22.9%; p = 0.730) and 30‐day mortality (1.0%, 0.6%, 0%). On multivariable analysis, neither concurrent hepatectomy (OR 1.02, 95% CI 0.71–1.48) nor concurrent ablation (OR 0.94, 95% CI 0.46–1.93) was associated with morbidity. Pancreatoduodenectomy was associated with morbidity (OR 2.38, 95% CI 2.05–2.76), reoperation (OR 2.16, 95% CI 1.52–3.08), and mortality (OR 2.50, 95% CI 1.39–4.50), and a minimally invasive approach was associated with lower morbidity (OR 0.69, 95% CI 0.60–0.80).
Conclusions
Concurrent liver‐directed surgery was not associated with an increase in 30‐day morbidity or mortality after pancreatectomy for pNETs. These findings support the safety of concurrent hepatic resection in appropriately selected pNET patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
- Department of Surgery, University of Maryland, Baltimore, Maryland, USA.
- Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
- Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Ashrita Raghuram, Sophia Xiao, Ethan Angle, Hassan Aziz
Zitieren
APA
Ebadinejad, A., Raghuram, A., Xiao, S., Angle, E., & Aziz, H. (2026). Perioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors. Journal of Surgical Oncology, 134(6), 830-839. https://doi.org/10.1002/jso.70352
Vancouver
Ebadinejad A, Raghuram A, Xiao S, Angle E, Aziz H. Perioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors. Journal of Surgical Oncology. 2026;134(6):830-839. doi:10.1002/jso.70352
BibTeX
@article{Ebadinejad2026,
author = {Ebadinejad, Amir and Raghuram, Ashrita and Xiao, Sophia and Angle, Ethan and Aziz, Hassan},
title = {Perioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors},
journal = {Journal of Surgical Oncology},
year = {2026},
volume = {134},
number = {6},
pages = {830--839},
doi = {10.1002/jso.70352}
}
EUVIMED